Market Research Report

Hepatitis Treatments and Vaccines: World Market 2012-2022
cover Published by Visiongain
Published Product code 240855
Content info 183 Pages
Price

Introduction

Abstract

Report Details

image1

How to find trends and revenue prospects for hepatitis-treating agents

Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.

This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.

You see forecasting of therapeutic submarkets to 2022, finding potential revenues:

  • Hepatitis B
  • Hepatitis C.

You also find revenue forecasting of product classes to 2022:

  • Oral antivirals
  • Interferons
  • Vaccines.

How will 10 leading products - including Baraclude, Pegasys, Incivek and PegIntron - perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.

The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.

Market value for 2012 and prospects for the future

What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.

We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.

What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.

The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.

High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.

Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.

Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.

Sales forecasts, market shares, developmental trends and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.

Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

  • Find potential revenues to 2022 for the world market and submarkets
  • Discover projected revenue trends of 10 leading brands to 2022
  • See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
  • Assess 7 leading companies, and other players, discovering activities and outlooks
  • Review R&D pipelines, seeing trends by therapeutic area
  • Investigate competition and opportunities influencing sales
  • Find out what will stimulate and restrain the industry and market
  • View opinions from the sector, seeing an interview with an external authority.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

Table of Contents

Table of Contents

1. Executive Summary

  • 1.1 Hepatitis Treatments and Vaccines: World Market Overview
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods

2. Introduction to Hepatitis

  • 2.1 Hepatitis: A Brief Overview
    • 2.1.1 Symptoms and Diagnosis
    • 2.1.2 Hepatitis B
      • 2.1.2.1 Hepatitis D
    • 2.1.3 Hepatitis C
    • 2.1.4 Hepatitis A
    • 2.1.5 Hepatitis E
  • 2.2 Risk Factors for Hepatitis
  • 2.3 Recent Trends in Incidence and Prevalence
  • 2.4 Hepatitis: Treatment and Prevention
    • 2.4.1 Antiviral Therapy
      • 2.4.1.1 Treatment with Interferon and Ribavirin
    • 2.4.2 Vaccines
      • 2.4.2.1 Hepatitis E Vaccine

3. The World Hepatitis Treatment and Vaccine Market 2012-2022

  • 3.1 The Hepatitis Treatment and Vaccine Market 2011
    • 3.1.1 The Hepatitis Treatment Market by Indication
    • 3.2 The Hepatitis Treatment and Vaccine Market: Overall Revenue Forecast 2012-2022
    • 3.2.1 Rising Awareness and Screening
    • 3.2.2 Generic Competition in the Hepatitis B Treatment Market
    • 3.2.3 Biosimilar Interferons
    • 3.2.4 Rise of Direct-Acting Antivirals (DAAs)
  • 3.3 Oral Antivirals Submarket 2011
    • 3.3.1 DAAs in Hepatitis B
    • 3.3.2 DAAs in Hepatitis C
    • 3.3.3 Oral Antivirals Submarket: Revenue Forecast 2012-2022
    • 3.3.4 A Long Pipeline
    • 3.3.5 All-Oral Treatment for Hepatitis C
  • 3.4 Interferons Submarket 2011
    • 3.4.1 Standard of Care for Hepatitis C
    • 3.4.2 Drawbacks to Interferon Therapy
    • 3.4.3 Declining Revenues 2008-2011
    • 3.4.4 Interferons Submarket: Revenue Forecast 2012-2022
    • 3.4.5 Next Generation Interferons in Development
  • 3.5 Hepatitis Vaccines Submarket 2011
    • 3.5.1 GSK: A Dominant Global Player
    • 3.5.2 Expanding Vaccination Programmes in Emerging Markets
    • 3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast 2012-2022
  • 3.6 Hepatitis Treatment and Vaccine Submarket Shares 2011, 2016 and 2022
  • 3.7 Hepatitis Treatment Market: Revenue Forecast by Indication 2012-2022

4. Leading National Hepatitis Treatment and Vaccine Markets 2012-2022

  • 4.1 Global Prevalence of Hepatitis 2012
    • 4.1.1 The Importance of Asia
  • 4.2 Hepatitis Treatment and Vaccine Market: Regional Breakdown 2011
  • 4.3 Hepatitis Treatment and Vaccine Market: Regional Forecast 2012-2022
  • 4.4 The US
    • 4.4.1 Population Movement and Hepatitis
    • 4.4.2 Screening for Hepatitis
    • 4.4.3 The US: Revenues 2012-2022
  • 4.5 Europe
    • 4.5.1 Regional Prevalence
    • 4.5.2 European Market 2011
    • 4.5.3 European Market: Revenue Forecasts 2012-2022
    • 4.5.4 Italy: Revenues 2012-2022
    • 4.5.5 Spain: Revenues 2012-2022
    • 4.5.6 Germany: Revenues 2012-2022
    • 4.5.7 UK: Revenues 2012-2022
    • 4.5.8 France: Revenues 2012-2022
  • 4.6 Hepatitis in Asia
  • 4.7 China
    • 4.7.1 Increased Vaccination
    • 4.7.2 Rising Middle Class
    • 4.7.3 Hepatitis C Outbreaks
    • 4.7.4 Domestic Drug and Vaccine Development
    • 4.7.5 China: Revenues 2012-2022
  • 4.8 Japan
    • 4.8.1 Hepatitis B and C in Japan
    • 4.8.2 Japan: Revenues 2012-2022
  • 4.9 India
    • 4.9.1 Low Awareness and Vaccination Rates
    • 4.9.2 India: Revenues 2012-2022

5. Leading Hepatitis Therapies: Market Prospects to 2022

  • 5.1 Leading Hepatitis B Therapies 2012-2022
  • 5.2 Baraclude (Bristol-Myers Squibb)
    • 5.2.1 Recent Revenue Analysis
    • 5.2.2 Patent Challenges
    • 5.2.3 Baraclude: Revenue Forecast 2012-2022
  • 5.3 Zeffix (GSK)
    • 5.3.1 Recent Revenue Analysis
    • 5.3.2 Resistance to Zeffix
    • 5.3.3 Generic Competition
    • 5.3.4 Zeffix: Revenue Forecast 2012-2022
  • 5.4 Hepsera (Gilead Sciences/GSK)
    • 5.4.1 Recent Revenue Analysis
    • 5.4.2 Patent Expiry and Generic Competition
    • 5.4.3 Switching to Viread
    • 5.4.4 Hepsera: Revenue Forecast 2012-2022
  • 5.5 Viread (Gilead Sciences)
    • 5.5.1 Recent Revenue Analysis
    • 5.5.2 GSK Licensing Agreement
    • 5.5.3 Prodrugs in Development
    • 5.5.4 Viread: Revenue Forecast 2012-2022
  • 5.6 Tyzeka (Novartis)
    • 5.6.1 Resistance and Competition
    • 5.6.2 Tyzeka: Revenue Forecast 2012-2022
  • 5.7 Leading Hepatitis B Vaccines 2012-2022
  • 5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
    • 5.8.1 Recent Revenue Analysis
    • 5.8.2 Demand and Supply in Emerging Markets
    • 5.8.3 Competition in the Pipeline
    • 5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast 2012-2022
  • 5.9 Leading Hepatitis C Therapies 2012-2022
  • 5.10 Pegasys (Roche)
    • 5.10.1 Recent Revenue Analysis
    • 5.10.2 Label Expansions and Lifecycle Management
    • 5.10.3 Pegasys: Revenue Forecast 2012-2022
  • 5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
    • 5.11.1 Revenue Analysis 2011
    • 5.11.2 Possible Label Expansion
    • 5.11.3 Incivek in Interferon-Free Regimens
    • 5.11.4 Pipeline Competition
    • 5.11.5 Incivek: Revenue Forecast 2012-2022
  • 5.12 PegIntron (Merck & Co.)
    • 5.12.1 Revenue Analysis 2011
    • 5.12.2 Biosimilar Competition
    • 5.12.3 Lifecycle Management
    • 5.12.4 PegIntron: Revenue Forecast 2012-2022
  • 5.13 Victrelis (Merck & Co.)
    • 5.13.1 Revenue Analysis 2011
    • 5.13.2 Roche Collaboration
    • 5.13.3 Product Differentiation
    • 5.13.4 Victrelis: Revenue Forecast 2012-2022

6. Hepatitis Treatment and Vaccine Market: Leading Pipeline Candidates 2012

  • 6.1 Leading Hepatitis C Pipeline Candidates 2012
    • 6.1.1 Alisporivir (Novartis/Debiopharm)
    • 6.1.2 BI 201335 (Boehringer Ingelheim)
      • 6.1.2.1 BI 207127 (Boehringer Ingelheim)
    • 6.1.3 Daclatasvir (Bristol-Myers Squibb)
      • 6.1.3.1 Asunaprevir (Bristol-Myers Squibb)
    • 6.1.4 GS-7977 (Gilead Sciences)
    • 6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir)
      • 6.1.5.1 TMC435 in All-Oral Regimens
    • 6.1.6 Vaniprevir (Merck & Co.)
    • 6.1.7 ABT-450 (Abbott Laboratories)
    • 6.1.8 ACH-1625 (Achillion Pharmaceuticals)
      • 6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
      • 6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
    • 6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals)
    • 6.1.10 Danoprevir (Roche)
    • 6.1.11 GI-5005 (GlobeImmune)
    • 6.1.12 IDX184 (Idenix Pharmaceuticals)
    • 6.1.13 INX-189 (Inhibitex)
    • 6.1.14 Locteron (Biolex)
    • 6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb)
    • 6.1.16 R7128 (Roche/Pharmasset)
    • 6.1.17 SCY-635
    • 6.1.18 Setrobuvir (Roche)
    • 6.1.19 Tegobuvir (Gilead Sciences)
    • 6.1.20 VX-222 (Vertex Pharmaceuticals)
  • 6.2 Leading Hepatitis B Pipeline Candidates 2012
    • 6.2.1 Heplisav (Dynavax Technologies)
    • 6.2.2 Rep 9AC' (REPLICor)
    • 6.2.3 Myrcludex B (MYR)
    • 6.2.4 AGX-1009 (Agenix)

7. Leading Companies in Hepatitis Treatment in 2012

  • 7.1 Leading Market Players, 2012
  • 7.2 Roche
    • 7.2.1 Product Overview and Performance 2011
    • 7.2.2 Recent Developments
    • 7.2.3 Hepatitis Pipeline
    • 7.2.4 Future Outlook
  • 7.3 GSK
    • 7.3.1 Product Overview and Performance 2011
    • 7.3.2 Recent Developments
    • 7.3.3 Hepatitis Pipeline
    • 7.3.4 Future Outlook
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Product Overview and Performance 2011
    • 7.4.2 Recent Developments
    • 7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
    • 7.4.3 Hepatitis Pipeline
    • 7.4.4 Future Outlook
  • 7.5 Merck & Co.
    • 7.5.1 Product Overview and Performance 2011
    • 7.5.2 Recent Developments
    • 7.5.3 Hepatitis Pipeline
    • 7.5.4 Future Outlook
  • 7.6 Vertex Pharmaceuticals
    • 7.6.1 Product Overview and Performance 2011
    • 7.6.2 Recent Developments
    • 7.6.3 Hepatitis Pipeline
    • 7.6.4 Future Outlook
  • 7.7 Gilead Sciences
    • 7.7.1 Product Overview and Performance 2011
    • 7.7.2 Gilead Acquires Pharmasset
    • 7.7.3 Hepatitis Pipeline
    • 7.7.4 Future Outlook
  • 7.8 Novartis
    • 7.8.1 Product Overview and Performance 2011
    • 7.8.2 Recent Developments
    • 7.8.3 Hepatitis Pipeline
    • 7.8.4 Future Outlook
  • 7.9 Leading Hepatitis Pipeline Companies
    • 7.9.1 Abbott Laboratories
    • 7.9.2 Achillion Pharmaceuticals
    • 7.9.2.1 Achillion and Gilead
    • 7.9.3 Boehringer Ingelheim
    • 7.9.4 Idenix Pharmaceuticals
      • 7.9.4.1 Idenix Pharmaceuticals: Outlook

8. Hepatitis Treatment and Vaccine Market: Industry Trends 2012-2022

  • 8.1 Strengths and Weaknesses in the Hepatitis Treatment and Vaccine Market 2011
    • 8.1.1 Resistance in Hepatitis B
    • 8.1.2 Interferon Therapy Has Drawbacks
    • 8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
  • 8.2 Opportunities and Threats in the Hepatitis Treatment and Vaccine Market 2012-2022
    • 8.2.1 Hepatitis Screening and Diagnosis
    • 8.2.2 Raising Awareness and Overcoming Social Stigma
    • 8.2.3 Personalised Therapy
    • 8.2.4 HIV Co-Infection
    • 8.2.5 Asia
  • 8.3 Hepatitis B Vaccination
  • 8.4 Limited Hepatitis B Pipeline
  • 8.5 Hepatitis C Vaccines
  • 8.6 Oral Direct-Acting Antivirals
    • 8.6.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
    • 8.6.2 Combining Protease and Polymerase Inhibitors
    • 8.6.3 The Need for Ribavirin
    • 8.6.4 Twelve Week Treatment Target
  • 8.7 Pharmaceutical Investment in Hepatitis C
    • 8.7.1 Licensing and Partnering Deals
    • 8.7.2 Acquisitions in Hepatitis C
    • 8.7.3 Future Targets for Collaboration or Acquisition

9. Research Interview

  • 9.1 Dr David Spencer, CEO, Biotechnology Enterprise Management
    • 9.1.1 Novel Interferon Development
    • 9.1.2 Performance in a Competitive Market
    • 9.1.3 Biosimilar Interferons
    • 9.1.4 Opportunities and Threats in the Hepatitis C Market

10. Conclusions

  • 10.1 State of the Hepatitis Treatment and Vaccine Market 2011
  • 10.2 Growth in the Hepatitis Treatment and Vaccine Market 2012-2022
    • 10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
    • 10.2.2 Weak Pipeline for Hepatitis B
  • 10.3 Asia as a Hepatitis Market

List of Tables

  • Table 1.1 Currency Exchange Rates, 2011
  • Table 1.2 Abbreviations and Acronyms Used in the Report
  • Table 2.1 Hepatitis Subtypes: An Overview
  • Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
  • Table 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
  • Table 3.2 Hepatitis Treatment Market by Indication, 2011
  • Table 3.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Sector, 2011-2022
  • Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2012
  • Table 3.5 Oral Antivirals Submarket: Drug Revenues, 2011
  • Table 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
  • Table 3.7 Interferons Submarket: Drug Revenues, 2011
  • Table 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
  • Table 3.9 Vaccines Submarket: Drug Revenues, 2011
  • Table 3.10 Vaccines Submarket: Revenue Forecast, 2011-2022
  • Table 3.11 Hepatitis Treatments and Vaccines: Submarket Shares, 2011, 2016 and 2022
  • Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts by Indication, 2011-2022
  • Table 4.1 Chronic Hepatitis B & C: Global Prevalence by Region, 2012
  • Table 4.2 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
  • Table 4.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Region, 2011-2022
  • Table 4.4 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.5 European Hepatitis Treatments and Vaccines: Market by Country, 2011
  • Table 4.6 European Hepatitis Treatment and Vaccine Market: Revenue Forecasts by Country, 2011-2022
  • Table 4.7 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.8 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.9 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.10 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.11 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.12 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.13 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 4.14 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Table 5.1 Baraclude: Key Facts, 2012
  • Table 5.2 Baraclude: Revenue by Region, 2009-2011
  • Table 5.3 Baraclude: Revenue Forecast, 2011-2022
  • Table 5.4 Zeffix: Key Facts, 2012
  • Table 5.5 Zeffix: Revenue by Region, 2010-2011
  • Table 5.6 Zeffix: Revenue Forecast, 2011-2022
  • Table 5.7 Hepsera: Key Facts, 2012
  • Table 5.8 Hepsera: Revenue by Company, 2009-2011
  • Table 5.9 Hepsera: Revenue Forecast, 2011-2022
  • Table 5.10 Viread: Key Facts, 2012
  • Table 5.11 Viread: Revenue Forecast, 2011-2022
  • Table 5.12 Tyzeka: Key Facts, 2012
  • Table 5.13 Tyzeka: Revenue, 2009-2011
  • Table 5.14 Tyzeka: Revenue Forecast, 2011-2022
  • Table 5.15 GSK's Hepatitis Vaccines: Key Facts, 2012
  • Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
  • Table 5.17 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
  • Table 5.18 Pegasys: Key Facts, 2012
  • Table 5.19 Pegasys: Revenue, 2009-2011
  • Table 5.20 Pegasys: Revenue Forecast, 2011-2022
  • Table 5.21 Incivek: Key Facts, 2012
  • Table 5.22 Incivek: Revenue by Region, 2011
  • Table 5.23 Incivek: Revenue Forecast, 2011-2022
  • Table 5.24 PegIntron: Key Facts, 2012
  • Table 5.25 PegIntron: Revenue Forecast, 2011-2022
  • Table 5.26 Victrelis: Key Facts, 2012
  • Table 5.27 Victrelis: Revenue Forecast, 2011-2022
  • Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
  • Table 6.2 Alisporivir: Phase III Trials, 2012
  • Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
  • Table 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
  • Table 7.2 Roche: Hepatitis Clinical Pipeline, 2012
  • Table 7.3 Pegasys: Revenues and Market Share, 2011, 2016 and 2022
  • Table 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
  • Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
  • Table 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
  • Table 7.7 Vertex Pharmaceuticals: Milestone Payments and Royalty Income for Telaprevir, 2004-2011
  • Table 7.8 Gilead Sciences: Revenue by Therapeutic Area, 2011
  • Table 7.9 Gilead Sciences: Hepatitis Clinical Pipeline, 2012
  • Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
  • Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
  • Table 8.1 Hepatitis Treatment and Vaccine Market: Strengths and Weaknesses, 2011-2012
  • Table 8.2 Hepatitis Treatment and Vaccine Market: Opportunities and Threats, 2012-2022
  • Table 8.3 Liver Cancer: Global Deaths by Region, 2008
  • Table 8.4 Hepatitis: Global Deaths by Region, 2008
  • Table 8.5 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
  • Table 8.6 Selected All-Oral Hepatitis C Regimens in Development, 2012
  • Table 8.7 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
  • Table 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022
  • Table 10.2 Hepatitis Treatments: Patent Expiries & Peak Revenues, 2008-2025

List of Figures

  • Figure 2.1 A Brief History of Hepatitis, 1947-2012
  • Figure 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
  • Figure 3.2 Hepatitis Treatment Market by Indication, 2011
  • Figure 3.3 Hepatitis Treatment and Vaccine Market: Overall Market Forecast, 2011-2022
  • Figure 3.4 Oral Antivirals Submarket: Drug Revenues, 2011
  • Figure 3.5 Oral Antivirals Submarket: Drivers and Restraints, 2012-2022
  • Figure 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
  • Figure 3.7 Interferons Submarket: Drug Revenues, 2011
  • Figure 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
  • Figure 3.9 Interferons Submarket: Drivers and Restraints, 2012-2022
  • Figure 3.10 Vaccines Submarket: Drug Revenues, 2011
  • Figure 3.11 Vaccines Submarket: Drivers and Restraints, 2012-2022
  • Figure 3.12 Vaccines Submarket: Revenue Forecast, 2011-2022
  • Figure 3.13 Hepatitis Treatment and Vaccine Market by Sector, 2016
  • Figure 3.14 Hepatitis Treatment and Vaccine Market by Sector, 2022
  • Figure 3.15 Hepatitis B Submarket: Drivers and Restraints, 2012-2022
  • Figure 3.16 Hepatitis B Submarket: Revenue Forecast, 2011-2022
  • Figure 3.17 Hepatitis C Submarket: Drivers and Restraints, 2012-2022
  • Figure 3.18 Hepatitis C Submarket: Revenue Forecast, 2011-2022
  • Figure 4.1 Chronic Hepatitis B: Global Prevalence by Region, 2012
  • Figure 4.2 Chronic Hepatitis C: Global Prevalence by Region, 2012
  • Figure 4.3 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
  • Figure 4.4 Hepatitis Treatments and Vaccines: Market Shares by Region, 2016
  • Figure 4.5 Hepatitis Treatments and Vaccines: Market Shares by Region, 2022
  • Figure 4.6 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.7 European Hepatitis Treatments and Vaccines: Market by Country, 2011
  • Figure 4.8 European Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.9 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.10 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.11 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.12 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.13 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.14 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.15 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 4.16 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
  • Figure 5.1 Baraclude: Revenue by Region, 2009-2011
  • Figure 5.2 Baraclude: Revenue Forecast, 2011-2022
  • Figure 5.3 Zeffix: Revenue by Region, 2011
  • Figure 5.4 Zeffix: Revenue Forecast, 2011-2022
  • Figure 5.5 Hepsera: Revenue by Company, 2009-2011
  • Figure 5.6 Hepsera: Revenue Forecast, 2011-2022
  • Figure 5.7 Viread: Revenue Forecast, 2011-2022
  • Figure 5.8 Tyzeka: Revenue, 2009-2011
  • Figure 5.9 Tyzeka: Revenue Forecast, 2011-2022
  • Figure 5.10 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
  • Figure 5.11 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
  • Figure 5.12 Pegasys: Revenue, 2009-2011
  • Figure 5.13 Pegasys: Revenue Forecast, 2011-2022
  • Figure 5.14 Incivek: Revenue by Region, 2011
  • Figure 5.15 Incivek: Revenue Forecast, 2011-2022
  • Figure 5.16 PegIntron: Revenue Forecast, 2011-2022
  • Figure 5.17 Victrelis: Revenue Forecast, 2011-2022
  • Figure 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
  • Figure 7.2 Pegasys: Revenues, 2011, 2016 and 2022
  • Figure 7.3 Roche: Key Events in the Hepatitis Market, 2012-2022
  • Figure 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
  • Figure 7.5 Bristol-Myers Squibb: Key Events in the Hepatitis Market, 2012-2022
  • Figure 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
  • Figure 7.7 Gilead Sciences: Revenue by Therapeutic Area, 2011
  • Figure 7.8 Gilead Sciences: Key Events in the Hepatitis Market, 2012-2022
  • Figure 8.1 Liver Cancer: Global Deaths by Region, 2008
  • Figure 8.2 Hepatitis: Global Deaths by Region, 2008
  • Figure 8.3 All-Oral Regimens: Projected Launches, 2012-2016
  • Figure 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022

Companies Listed

  • 3SBio
  • Abbott Laboratories
  • Abbott Molecular
  • Achillion Pharmaceuticals
  • Agenix
  • Alios BioPharma
  • American University in Cairo
  • Anadys Pharmaceuticals (now part of Roche)
  • Anhui Biochem Bio-Pharmaceutical
  • Apotex
  • Aurobindo Pharma
  • Beijing Key Yuan Xinhai Pharmaceutical
  • Beijing Wantai Biological Pharmacy Enterprise
  • BioCryst Pharmaceuticals
  • Biogen Idec
  • Biolex
  • BioLineRx
  • BioPhausia (now part of Medivir)
  • Biota Holdings
  • Biotechnology Enterprise Management
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Centers for Disease Control and Prevention (CDC) [US]
  • China NT Pharma Group
  • Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
  • Chiron (now part of Novartis)
  • ChronTech Pharma
  • Chugai Pharmaceutical (part of Roche)
  • Codexis
  • Compass Biotechnologies
  • Corvas International (now part of Dendreon)
  • CPP Investment Board
  • Debiopharm
  • Dendreon
  • Drug Controller General of India (DCGI)
  • Dynavax Technologies
  • Eli Lilly
  • EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
  • Enanta Pharmaceuticals
  • European Association for the Study of the Liver (EASL)
  • European Commission (EC)
  • European Liver Patients Association (ELPA)
  • European Medicines Agency (EMA)
  • Feron
  • Food and Drug Administration (FDA) [US]
  • Genelabs Technologies (now part of GSK)
  • Genoscience
  • Getz Pharma
  • Gilead Sciences
  • GlobeImmune
  • GSK
  • Hainan Zhonghe Pharmaceutical
  • Health Protection Agency (HPA) [UK]
  • Hepatera
  • High-Tech Grunderfonds
  • Hualida Biotech
  • Idenix Pharmaceuticals
  • Imperial College London
  • Inhibitex (now part of BMS)
  • Inovio Pharmaceuticals
  • Institut de Veille Sanitaire (InVS) [France]
  • Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
  • Institut National de la Sante et de la Recherche Medicale (INSERM) [France]
  • InterMune
  • J&J
  • Janssen Pharmaceutica (a subsidiary of J&J)
  • Kadmon Pharmaceuticals
  • Kun Run Biotechnology
  • LG Life Sciences
  • Maxwell Biotech Venture Fund
  • Medgenics
  • Medivir
  • Medtronic
  • Merck & Co.
  • Minapharm Pharmaceuticals
  • Ministry of Health [China]
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma
  • MYR
  • Nanogen Biopharmaceutical
  • Natco Pharma
  • National Health Service (NHS) [UK]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • Novartis
  • OctoPlus
  • Okairos
  • Oxford University
  • Pharmasset (now part of Gilead)
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Reliance Life Sciences
  • REPLICor
  • Rhein Biotech (now part of Dynavax Technologies)
  • Roche
  • Sanofi Pasteur
  • Schering-Plough (now part of Merck & Co)
  • SciClone Pharmaceuticals
  • Scottish Medicines Consortium (SMC)
  • SCYNEXIS
  • Sigmapharm Laboratories
  • Sinopharm Group
  • State Food and Drug Administration (SFDA) [China]
  • Teva
  • The Vaccine Fund
  • Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
  • Transgene
  • University of Alberta
  • University of Heidelberg
  • Valeant Pharmaceuticals International
  • Vertex Pharmaceuticals
  • ViroChem Pharma (now part of Vertex)
  • Welsh School of Pharmacy (Cardiff University)
  • World Health Organization (WHO)
  • World Hepatitis Alliance
  • Xiamen Innovax Biotech
  • Xiamen University
  • Zuellig Pharma
  • Zydus Cadila
  • ZymoGenetics (now part of BMS)

Hepatitis Treatments and Vaccines: World Market 2012-2022 published by Visiongain in May 2, 2012. This report consists of 183 Pages and the price starts from US $ 2739.

Back to Top